Liquidia enters amended supply agreement with Lonza for YUTREPIA; increased minimum commitments, FDA timeline triggers

Liquidia Corp

Amended Commercial Manufacturing Services and Supply Agreement with Lonza Tampa for encapsulation/packaging of YUTREPIA (treprostinil) inhalation powder.
Initial term of 5 years from FDA regulatory approval; Lonza may terminate if FDA does not approve by December 31, 2024.
Minimum annual order quantities materially increased compared to prior agreement; company may adjust after 13 months post-approval.
Upon termination for FDA rejection or delay, Liquidia reimburses 50% of Lonza capital equipment costs, cap $2.5 million.
Company delivers bulk treprostinil powder; Lonza provides encapsulation and storage services as sole supplier.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

Liquidia Corp amended Amended and Restated Commercial Manufacturing Services and Supply Agreement with Lonza Tampa LLC f/k/a Xcelience LLC (effective 2023-07-14).

Action: amendment
Agreement: supply
Counterparty: Lonza Tampa LLC f/k/a Xcelience LLC
Effective: 2023-07-14

Exact text from the filing

On July 14, 2023, Liquidia Corporation, a Delaware corporation through Liquidia Technologies, Inc., a Delaware corporation (the “Company”) and wholly owned subsidiary of Liquidia Corporation, entered into an Amended and Restated Commercial Manufacturing Services and Supply Agreement (the “Agreement”) with Lonza Tampa LLC f/k/a Xcelience LLC (“Lonza”).

View on SEC.gov

Browse all material agreements →

Liquidia Corp filing history →

Source: SEC EDGAR

accession 0001104659-23-081684

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.